Clinical Trial

Exploration of the Association Between White Matter Lesion Burden and Dalfampridine Response in Insidious-Onset Vascular Parkinsonism

Study acronym: DAL-VaP
Completed
View on ClinicalTrials.gov →
Summary
This single-center observational cohort study will be conducted at Tangdu Hospital, Fourth Military Medical University. Patients presenting parkinsonism and poor levodopa response will be enrolled, including insidious-onset vascular parkinsonism (VaP) and Parkinson-plus syndromes (PPS). Within each diagnostic subgroup, participants will receive either dalfampridine 10 mg twice daily for 4 weeks combined with conventional therapy, or conventional therapy alone. Change in Timed Up and Go (TUG) time, gait speed, balance, daily function, and quality of life metrics assessed from baseline to Week 4.
Trial Details
NCT Number NCT07682428
Lead Sponsor Tang-Du Hospital
Conditions Vascular Parkinsonism
Enrollment 72 participants
Start Date 2023-08-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02